Download Files:

Cosalane

Products Details

Product Description

– Cosalane (NSC 658586) is a potent inhibitor of HIV replication. Cosalane has an intrinsic ability to block human and murine CCR7 function in vitro in response to both of its natural ligands, CCL19 and CCL21, with the IC50 of 0.207/2.66 μM in human for CCL19/CCL21 and 0.193/1.98 μM in murine, respectively[1][2].

Web ID

– HY-120427

Shipping

– Room temperature

Molecular Formula

– C45H60Cl2O6

References

– [1]Kenneth A Fowler, et al. The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models. Biol Blood Marrow Transplant. 2019 Jun;25(6):1062-1074.|[2]Emily A Hull-Ryde, et al. Identification of Cosalane as an Inhibitor of Human and Murine CC-Chemokine Receptor 7 Signaling via a High-Throughput Screen. SLAS Discov. 2018 Dec;23(10):1083-1091.

CAS Number

– 154212-56-3

Molecular Weight

– 767.86

SMILES

– CC(CCC[C@H]([C@H]1CC[C@]2([C@@]3(CC[C@]4(C[C@H](CC[C@@]4([C@]3(CC[C@]12C)[H])C)CC/C=C(C5=CC(C(O)=O)=C(C(Cl)=C5)O)/C6=CC(C(O)=O)=C(C(Cl)=C6)O)[H])[H])[H])C)C

Clinical Information

– No Development Reported

Research Area

– infection

Solubility

– 10 mM in DMSO

Target

– CCR;HIV

Isoform

– CCR7

Pathway

– Anti-infection;GPCR/G Protein;Immunology/Inflammation

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.